|
THE INFORMATION IN THE OBPHARMTM
IS INTENDED SOLELY FOR USE BY THE MEDICAL PROFESSION. IT IS NOT INTENDED FOR LAY PERSONS.
FOCUS INFORMATION TECHNOLOGY, INC. DOES NOT ASSUME ANY RESPONSIBILITY FOR ANY ASPECT OF
HEALTHCARE ADMINISTERED WITH THE AID OF THIS CONTENT. THE PRESCRIBING PHYSICIAN
MUST BE FAMILIAR WITH THE FULL PRODUCT LABELING AS PROVIDED BY THE MANUFACTURER AND RELEVANT MEDICAL LITERATURE PRIOR TO USING THE
OBPHARMM
CHANGES MAY OCCUR SINCE THE LAST
UPDATE WHICH AFFECT THE ACCURACY AND AVAILABILITY OF THE INFORMATION PRESENTED
.
Oseltamivir phosphate(Tamiflu
®) [1.4]
Antiviral, neuraminidase inhibitor. Oseltamivir interferes with host cell
release of complete viral particles. M.W. 410.4
Adults
- Treatment of influenza
(13 years and older)
75-mg capsule orally twice per day for 5 days
- Chemoprophylaxis of influenza (13 years and older)
75-mg capsule once per day for 10 days after the last close contact (within
6 feet) with a person who is a confirmed, probable or suspected case of novel
influenza A (H1N1) virus infection during the infectious period of the case.
Community outbreak: 75 mg once daily for up to 6 weeks
Trivalent inactivated influenza vaccine can be administered at any time
relative to use of TAMIFLU
Reduce dosage in renally impaired patients
(30, 45, 75 mg capsules; Available in blister packages of 10)
Tamiflu package insert Genentech, Inc. 12/2014
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee3c9555-60f2-4f82-a760-11983c86e97b
https://pubchem.ncbi.nlm.nih.gov/compound/78000
Breast feeding "Limited data
indicate that oseltamivir and its active metabolite are poorly excreted into
breastmilk. Maternal dosages of 150 mg daily produce low levels in milk and
would not be expected to cause any adverse effects in breastfed infants,
especially if the infant is older than 2 months. Infants over 1 year of age can
receive oseltamivir directly in doses much larger than those in breastmilk."
LAACTMED 12/2015
Zanamivir ( Relenza
®) [1]
Antiviral, neuraminidase inhibitor . Prevents the
release of progeny viruses from host cell surfaces and, so, further viral
replication. M.W. 332.3 Adults
- Treatment of influenza (7 years of age or older)
10 mg (two inhalations) twice a day for 5 days
- Chemoprophylaxis of influenza (5 years of age or older)
Household: 10 mg (two inhalations) once per day for 10
days
after the last close contact (within 6 feet) with a person who is a
confirmed, probable or suspected case of novel influenza A (H1N1) virus
infection during the infectious period of the case.
Community outbreak: 10 mg (two inhalations) once per day for 28
days
Not recommended for treatment or prophylaxis of influenza in individuals
with underlying airways disease (such as asthma or chronic obstructive
pulmonary disease) due to risk of serious bronchospasm
(5 mg blisters of powder on a ROTADISK for oral inhalation via DISKHALER.
Packaged in carton containing 5 ROTADISKs (total of 10 doses) and 1 DISKHALER
inhalation device)
Relenza package insert GlaxoSmithKline LLC. 10/2013
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7c3bcc3-0c0d-4068-fd80-88cf54a376ef
https://pubchem.ncbi.nlm.nih.gov/compound/60855
Breast feeding
REFERENCES
1. Recommendations for Obstetric Health Care Providers Related to Use of
Antiviral Medications in the Treatment and Prevention of Influenza Centers for
Disease Control and Prevention March 6, 2015. [Accessed 12/13/2015]
Available from:
http://www.cdc.gov/flu/professionals/antivirals/avrec_ob.htm
2.Tanaka
T, et al "Safety of neuraminidase inhibitors against novel influenza A (H1N1) in
pregnant and breastfeeding women" CMAJ 2009; DOI:10.1503/cmaj.090866. Accessed
7-19-09
3.
Briggs GG,Freeman RK, Yaffe SJ, Drugs in Pregnancy and Lactation 9th
edition,Baltimore, MD: Williams & Wilkins,2011 p 1083 -84,1596 -1597 , 19
-23,1533 -1535
4.
Wollenhaupt M, et al., . The safety of oseltamivir in pregnancy: an updated
review of post-marketing data. Pharmacoepidemiol Drug Saf. 2014 Jul 4. doi:
10.1002/pds.3673. PMID:24995623
5.
Xie HY, et. Al., Infant outcomes among pregnant women who used oseltamivir for
treatment of influenza during the H1N1 epidemic. Am J Obstet Gynecol. 2013
Apr;208(4):293.e1-7. PMID:23333544
6.Saito S, et. al., Outcomes of infants exposed to oseltamivir or zanamivir in
utero during pandemic (H1N1) 2009. Am J Obstet Gynecol. 2013
Aug;209(2):130.e1-9. PMID:24995623
7.
Dunstan HJ, et. al., Pregnancy outcome following maternal use of zanamivir or
oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective
surveillance study. BJOG. 2014 Jun;121(7):901-6.PMID:24602087
|
